Stellantis N.V. Common Shares vs 22nd Century Group Inc — how do they compare? Stellantis N.V. Common Shares trades at $4.3 (market cap $16.51B), while 22nd Century Group Inc trades at $0.65 (market cap $475.95K). The key difference: Stellantis N.V. Common Shares is far larger — about 34688.5× 22nd Century Group Inc's market cap, and 22nd Century Group Inc is more actively traded (78,911 versus 28,274,156). Which is the better fit depends on your goals — on Pluang, investors hold Stellantis N.V. Common Shares for 0 Days and 22nd Century Group Inc for 33 Days on average.
| STLA | XXII | |
|---|---|---|
Market Cap | $16.51B | $475.95K |
Volume | 28,274,156 | 78,911 |
Sector | Consumer Cyclical | Consumer Staples |
52-Week High | $12.12 | $483.00 |
52-Week Low | $4.27 | $0.65 |
Typical Hold Time | 0 Days | 33 Days |
Enterprise Value | $36.19B | -$3.83M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XXII trades at $0.67, down 7.98% in the last session, with a bearish technical signal from moving averages. The company shows negative profitability metrics including -76.01% net income margin and -284.5% ROE, though valuation ratios appear low with P/S of 0.06 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives in France and Europe.
Despite analyst optimism (75% buy ratings with $1,240 price target), fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock faces significant execution risk in commercializing reduced-nicotine tobacco products while navigating regulatory timelines.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Stellantis N.V. is a multinational automaker formed from the 2021 merger of Fiat Chrysler Automobiles and PSA Group, manufacturing vehicles under brands including Jeep, Ram, Chrysler, Dodge, Fiat, Peugeot, and Citroën.
Read more on STLA →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →